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Abstract
Purpose—MRI is increasingly used for detection of breast carcinoma. Little is known about
breast MRI techniques among community practice facilities. This study evaluated equipment and
acquisition techniques used by community facilities across the U.S., including compliance with
minimum standards by the American College of Radiology Imaging Network (ACRIN) 6667 Trial
and the European Society of Breast Imaging (EUSOBI).
Methods—Breast Cancer Surveillance Consortium (BCSC) facilities performing breast MRI
were identified and queried by survey regarding breast MRI equipment and technical parameters.
Variables included scanner field strength, coil type, acquisition coverage, slice thickness and
timing of initial post-contrast sequence. Results were tallied and percentages of facilities meeting
ACRIN and EUSOBI standards were calculated
Results—From 23 facilities performing breast MRI, results were obtained from 14 (61%)
facilities with 16 MRI scanners reporting 18 imaging parameters. Compliance with equipment
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recommendations of ≥1.5T field strength was 94% and of a dedicated breast coil was 100%.
Eight-three percent of acquisitions used bilateral post-contrast technique and 78% used slice
thickness <= 3 mm. Timing of initial post-contrast sequences ranged from 58 seconds to eight
minutes 30 seconds, with 63% meeting recommendations for completion within four minutes.
Conclusions—Nearly all surveyed facilities met ACRIN and EUSOBI standards for breast MRI
equipment. The majority met standards for acquisition parameters, although techniques varied, in
particular for timing of initial post-contrast imaging. Further guidelines by the ACR Breast MRI





Breast MRI is an important new tool for the detection and characterization of breast
carcinoma. Applications for MRI of the breast include evaluation of the extent of ipsilateral
malignancy and screening of the contralateral breast in patients with newly diagnosed breast
cancer (1–25), screening of asymptomatic women at high risk for breast cancer (26–34) and
evaluation of patients with metastatic axillary adenopathy with an unknown primary cancer
(35–40). Due to the high sensitivity of MRI for breast cancer detection, several medical
organizations including the American Cancer Society (ACS) and the National
Comprehensive Cancer Coalition Network (NCCN) now recommend that women with
particular high risk factors for breast cancer undergo annual screening breast MRI in
addition to mammography (41–43). The NCCN guidelines also recommend that women
with a new breast cancer diagnosis consider breast MRI in the pre-operative setting (44,45).
Despite the increasingly widespread use of breast MRI, there are currently few guidelines
for standardization of image acquisition techniques. Compared to mammography and
ultrasound, which rely upon morphologic features for lesion characterization, evaluation
using breast MRI depends upon both lesion morphology and lesion kinetics. Assessment of
these MRI lesion features requires optimization of multiple aspects of technical
performance, including scanner field strength and coil selection for adequate signal-to-noise
ratio, spatial resolution for lesion morphology and timing of post-contrast imaging for lesion
kinetics. Currently, acquisition parameters specified by the American College of Radiology
Imaging Network (ACRIN) 6667 Trial (46) and the European Society of Breast Imaging
(EUSOBI) (47) provide reasonable minimum technical benchmarks for the performance of
high quality breast MRI (Table 1).
As its use has expanded, breast MRI has been adopted by community practice facilities,
where most women undergo breast imaging in this country. However, little is known about
the technical quality of MRI performed at US community facilities. Some variation in
technique is expected given the complexity of MRI, but significant deviation from minimum
technical specifications is a concern as it could compromise patient outcomes when
compared to those demonstrated in carefully controlled clinical trials. Providing quality care
and documenting practice within specified standards are increasingly important as pay-for-
performance is adopted including for medical imaging. The Medicare Improvements for
Patients and Providers Act of 2008 (MIPPA) calls for providers of advanced diagnostic
imaging services (MR, CT, PET, and nuclear medicine) to be accredited by 2012 in order to
receive Centers for Medicare and Medicaid Services (CMS) payment for the technical
component of those services. An assessment of MRI protocols used by a spectrum of
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community practice facilities across the country is important to understand the quality of
breast MRI care women receive in the United States.
The purpose of this study was to evaluate breast MRI equipment and acquisition techniques
currently used among a variety of community practice facilities across the United States,
using data from the Breast Cancer Surveillance Consortium (BCSC), and to determine the
compliance with current minimum standards as specified by ACRIN 6667 and the EUSOBI.
Methods
This study was a pilot project within the Breast Cancer Surveillance Consortium (BCSC)
funded by the National Cancer Institute. The BCSC is a research resource for studies
designed to assess the delivery and quality of breast cancer screening and related patient
outcomes in the United States. The BCSC is a collaborative network of five active breast
imaging registries with linkages to tumor and/or pathology registries and is supported by a
central Statistical Coordinating Center (SCC).
The BCSC population is the largest to-date for the study of breast imaging performance in
community practice across the United States (48,49). Currently, the Consortium’s database
contains information on 8.6 million mammography examinations, 2.3 million women and
101,300 breast cancer cases (84,800 invasive and 16,500 in situ cancers). Each breast
imaging registry and the SCC have received IRB approval for either active or passive
consenting processes or a waiver of consent to enroll participants, link data, and perform
analytic studies. All procedures are Health Insurance Portability and Accountability Act
(HIPAA) compliant and all registries and the SCC have received a Federal Certificate of
Confidentiality and other protection for the identities of women, physicians, and facilities
who are subjects of this research.
To assess the current use and quality of breast MRI performed in the BCSC, two surveys
were developed and distributed to BCSC radiology facilities. The first was a facility survey,
sent by each of the registries to their individual facilities (distributed in February 2008 and
returned in March 2008, Appendix A). A total of 98 facilities were queried. This survey
asked facilities if they performed breast MRI, and if so whether they would be willing to
complete a survey of MRI techniques. The survey also asked those facilities not performing
breast MRI to indicate whether they referred patients for breast MRI to facilities not in the
BCSC, and whether they intended to begin performing MRI in the future. The second survey
was a breast MRI technique survey, completed by the 23 facilities found to currently
performed breast MRI (distributed in February 2008 and returned in April 2008, Appendix
B). MRI performing facilities were asked to indicate their current equipment and technical
parameters for breast MRI. Each facility was asked to specify their MRI scanner field
strength, the year the MRI scanner was acquired and the type of coil used (dedicated breast
coil vs. non-breast coil). For imaging parameters, facilities were asked to specify the most
frequent MRI sequence used for contrast-enhanced imaging, the coverage of their
acquisitions (unilateral vs. bilateral), acquisition plane, slice thickness in mm, field of view
(FOV) in cm, matrix size, timing of initial post-contrast sequence (defined as time between
end of contrast injection and end of initial post-contrast sequence) and administered contrast
dose. Facilities personnel were able to ask their project managers for clarification regarding
the survey questions.
For our analysis, we tallied the results of responses to the facility surveys and the breast
MRI technique surveys. For the technique responses, the numbers and percentages of
facilities meeting the ACRIN 6667 and EUSOBI minimum technique standards were
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calculated. The researchers were blinded to facility identification information for data
analysis.
Results
The five BCSC registries reported that they had a total of 98 imaging facilities. 92/98 (94%)
of the facilities responded regarding their use of breast MRI. A total of 25% (23/92) of the
responding facilities reported that they were currently performing breast MRI, 14% (13/92)
were planning to perform MRI in the future and 20% (19/92) referred patients to facilities
not in the BCSC for breast MRI. Of the facilities performing breast MRI, 61% (14/23)
completed the second survey regarding their MRI equipment and acquisition techniques.
The 14 responding facilities filled out an MRI technique survey for each MRI scanner and
one facility had three MRI scanners, resulting in technique results for 16 MRI scanners. For
two of the 16 scanners, imaging parameters were reported for two separate primary post-
contrast imaging planes, resulting in 18 imaging parameter responses for the 16 scanners.
Table 1 summarizes the minimum standards for breast MRI equipment and imaging
technique specified by the ACRIN 6667 Trial and the EUSOBI. Table 2 provides the
detailed responses for the16 MRI scanners with 18 imaging parameters. Table 3 provides the
percentages of equipment and imaging parameters meeting the ACRIN 6667 and EUSOBI
minimum technique standards for the measured variables.
For MRI equipment used at the BCSC facilities, compliance with minimum standards was
94% (15/16) for scanner field strength ≥ 1.5T (ACRIN and EUSOBI standards). The MRI
scanners at the facilities were acquired from 1993 to 2007, with a mean year of acquisition
of 2003. Adherence was 100% (16/16) for use of a dedicated breast coil (ACRIN, EUSOBI).
A broad range of acquisition techniques were reported. Compliance was (83%) 15/18 for
bilateral post-contrast technique (EUSOBI standard). The remaining17% (3/18) of post-
contrast sequences were performed only unilaterally. Compliance was 78% (4/18) for
minimum standard of slice thickness <= 3 (ACRIN). For FOVs, compliance was 67% (2/3)
for dedicated unilateral acquisitions for the standard of <= 20 mm, and was 78% (7/9) for
bilateral acquisitions for the standard of <= 36 mm (ACRIN). Timing of the initial post-
contrast series, defined as time between end of contrast injection and end of initial post-
contrast acquisition, ranged from a minimum of 58 seconds to a maximum of eight minutes
30 seconds. Compliance was 63% (10/16) compared to the standard of initial post-contrast
sequence completed within four minutes after contrast administration (ACRIN). Comparison
with the EUSOBI standard for post-contrast timing is not possible, as their designated <= 2
minutes is for acquisition time without consideration of a delay prior to contrast
administration but before initiation of imaging. Contrast dose was varied, with 4/17 (23%)
acquisitions using weight-based dosing of 0.1 mmol/kg, and the remaining 13 using fixed
doses ranging from 20–30 mL (for an average 70 kg woman and a gadolinium agent with
typical concentration of .05 mol/L, 20–30 mL correspond to weight based doses
approximately in the 0.1 mmol/kg to 0.2 mmol range).
Conclusions
Most women in the United States undergo breast imaging at community practice facilities,
and these facilities have increasingly adopted breast MRI for a variety of clinical
indications. Breast MRI is highly sensitive, but is a complex tool for which appropriate use
requires optimization of multiple technical parameters. This study provides important
information for understanding the quality of breast MRI that is taking place in community
practice in the United States. Adherence to minimum technical standards is key to achieve
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the clinical outcomes that have been demonstrated in research trials evaluating both
morphologic and kinetic features of MRI findings.
To date, there have been few established guidelines for image acquisition for breast MRI.
The ACR BI-RADS Atlas now includes a section dedicated to breast MRI (50). However,
this initial MRI iteration is focused on the MRI lesion description lexicon and the technical
guidelines are limited. The sole imaging parameters specified in the MRI section are that a
dedicated breast coil is used, and that initial enhancement is measured within the first two
minutes and delayed enhancement after two minutes following contrast administration.
Currently, acquisition parameters specified by the American College of Radiology Imaging
Network (ACRIN) 6667 Trial (46) and the European Society of Breast Imaging (EUSOBI)
(47) provide reasonable minimum technical benchmarks for the performance of high quality
breast MRI. The ACRIN 6667 trial evaluated MRI of the contralateral breast in women with
a recently diagnosed breast cancer and had 25 practice sites in the U.S., Canada and
Germany. Although these standards were developed several years ago and are less than the
spatial and temporal resolution now achievable, adherence to these parameters resulted in a
sensitivity of 91% for contralateral breast cancer. More recently, the EUSOBI published its
guidelines for breast MRI (44). The key minimum requirements from the ACRIN and
EUSOBI are summarized in Tables 1.
In our study, we found that adherence to minimum standards for breast MRI equipment
across community practice facilities was excellent, with 94% of scanners having ≥ 1.5T
field strength, and all scanners employed a dedicated breast coil, as recommended by both
ACRIN and the EUSOBI. These results are reassuring, as higher field strength imaging and
use of a dedicated breast coil are requirements to optimize signal-to-noise.
Our results regarding imaging parameters were varied, and illustrate the heterogeneous
nature of breast MRI acquisition. The majority (83%) of acquisitions complied with
minimum standards of performing bilateral imaging, although we found that 17% of post-
contrast sequences were performed only unilaterally. While historically it was necessary to
perform unilateral imaging to achieve high spatial resolution, technologic improvements
now allow imaging of both breasts without compromise of spatial or temporal resolution.
Bilateral imaging is desirable, as both breasts warrant evaluation in women undergoing MRI
for risk screening or those with a new cancer diagnosis being assessed for extent of disease.
Further, scanning both breasts allows important comparison of the symmetry of bilateral
enhancement, a method which can help prevent diagnostic errors (51). The majority (78%)
of acquisitions also met minimum standards for slice thickness of <= 3 mm. Compliance
was lower (63%) for completion of the initial post-contrast sequence within four minutes
after contrast administration. Some facilities reported completion of initial post-contrast
imaging over eight minutes after contrast administration. Due to the typically rapid and
transient enhancement of breast cancers, sequences obtained within four minutes after
contrast administration are considered the minimum temporal resolution, with the ACR BI-
RADS and others advocating two minute temporal resolution..
In conclusion, we found that nearly all of our studied community practice facilities met
minimum standards for MRI equipment. The majority also met key standards for imaging
parameters, although techniques were varied and outliers with respect to temporal resolution
in particular were identified. There are limitations to our study. Although it was the first
investigation of this topic, it was a pilot study, and our sample size was 14 facilities
reporting 16 scanners performing breast MRI. Further, we did not assess MR images for
quality, nor ask facilities about whether they performed MRI guided biopsy, an important
standard for a quality breast MRI practice. In addition, due to technical advances, imaging
techniques may have evolved in the interval since facilities were surveyed.
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Importantly, the ACR has recently opened its Breast MRI Accreditation Program. It is
currently voluntary, and includes minimum specifications for performing and interpreting
breast MRI. However, outpatient providers are required by HIPPA to be accredited for
breast MRI by January, 2012 for CMS reimbursement, and the ACR Program has been
approved for this certification. Mandatory FDA accreditation for mammography facilities by
the Mammography Quality Standards Act (MQSA) is widely acknowledged to have
improved the quality of imaging using this modality. It is expected that the ACR Breast MRI
Accreditation Program will similarly facilitate standardized and quality care for women
undergoing breast MRI in this country. Of note, in the 10 years following MQSA
implementation, the number of certified facilities performing mammography declined by
approximately 10%, likely in part due to inability to meet FDA standards (52). However, the
total number of mammography units across the country actually increased in this time period
(52). Accreditation for breast MRI may impact not only the technique but also the
distribution of sites offering this imaging test.
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Appendix A. Breast Cancer Surveillance Consortium Breast MRI
SITE FACILITIES SURVEY
Name/ID of Site: _______________
Instructions: One form to be completed per site facility.
Facility Name: _______________
Encrypted ID: __________
1. Is breast MRI performed at your facility?
___Yes- go to 2
___No-go to 3 &
2. If yes, (breast MRI performed at your facility):
a. Would you be willing to fill out a survey (attached) regarding the technical
details of how you perform breast MRI?
___Yes- please fill out attached Facility MRI Technique Survey
Form
___No





3. If no breast MRI is performed at your facility:
a. Are patients referred for breast MRI to other facilities outside the BCSC?
___Yes- go to 3b
___No




4. If no breast MRI is performed at your facility, do you anticipate offering breast
MRI in the future?
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Appendix B. Breast Cancer Surveillance Consortium Breast MRI
FACILITY MRI TECHNIQUE SURVEY




Scanner _____ of _____ total scanners
MRI Scanner Used for Breast MRI: __________ Date scanner acquired: __________
Manufacturer __________ Model __________ Field Strength __________ Tesla
Dedicated Breast Coil? □Yes □No □Unilateral □Bilateral Date breast coil acquired? _____
MR Pulse Sequence Used for Contrast-enhanced Imaging:
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Contrast Agent Used: _____ Dose: _____ Rate of Admin: _____ Saline Flush? □Yes □No.
If yes, volume of saline used: _____
In your breast MRI program, is CAD applied to breast MRI?
___Yes ___NO





List all radiologists (and their encrypted IDs) who interpret breast MRIs at your facility:
_______________
_______________
In the future, would you be willing to either fill out a data form or electronically send these
data to the (name of site) for each MRI performed at your facility (see attached sample of
data variables to be collected**)?
____Yes____NO
**Sample of data variables to be collected for each breast MRI:
Patient ID (full name, DOB)
Date of breast MRI exam
Clinical Indication for breast MRI
___Newly diagnosed breast cancer (staging/extent of disease)
___High risk screening
___Problem solving for equivocal clinical or imaging finding
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